ArticleFrontiers in microbiology2021
Brevibacillin 2V, a Novel Antimicrobial Lipopeptide With an Exceptionally Low Hemolytic Activity.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Purification, Characterization, and In Vitro Safety Assessment of the Antimicrobial Peptide SAM-KB40 from Bacillus licheniformis SAM-D318.Applied biochemistry and biotechnology · 2026Article
- Infection control and anti-apoptotic effect of Lactobacillus paracasei derivatives on fibroblasts through modulation of BCL2 transcription.Archives of microbiology · 2026Article
- Arctic deep-sea hydrothermal microbiomes as a natural niche for novel antimicrobial peptides.BMC microbiology · 2026Article
- Lipopeptide Engineering: From Natural Origins to Rational Design Against Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- The interaction of small molecules with phospholipid membranes studied by solid-state NMR and molecular dynamics simulation.Biophysical reviews · 2025Review
- Discovery of a Novel Antimicrobial Peptide fromAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Activity of a Synthetic Brevibacillin Analog Against Multidrug-ResistantInternational journal of molecular sciences · 2025Article
- Structure-Activity Study of the Antimicrobial Lipopeptide Humimycin A and Screening Against Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Investigating the production and synergistic antibacterial activity of bacteriocin-like substance fromHeliyon · 2025Article
- Guiding antibiotics towards their target using bacteriophage proteins.Nature communications · 2024Article
- Effects of a novelHeliyon · 2024Article
- Review
- New N-Terminal Fatty-Acid-Modified Melittin Analogs with Potent Biological Activity.International journal of molecular sciences · 2024Article
- Lipopeptide adjuvants for antibiotics and vaccines: the future step in the fight against multidrug-resistant and extensively drug-resistant pathogens.Exploration of drug science · 2024Article
- Article
- Searching for Antimicrobial-Producing Bacteria from Soils through an Educational Project and Their Evaluation as Potential Biocontrol Agents.Antibiotics (Basel, Switzerland) · 2023Article
- Combating Antimicrobial Resistance in the Post-Genomic Era: Rapid Antibiotic Discovery.Molecules (Basel, Switzerland) · 2023Review
- Elucidating the Mechanism of Action of the Gram-Negative-Pathogen-Selective Cyclic Antimicrobial Lipopeptide Brevicidine.Antimicrobial agents and chemotherapy · 2023Article
- Brevicidine acts as an effective sensitizer of outer membrane-impermeable conventional antibiotics forFrontiers in microbiology · 2023Article
- Expanding the Landscape of Amino Acid-Rich Antimicrobial Peptides: Definition, Deployment in Nature, Implications for Peptide Design and Therapeutic Potential.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial non-ribosomally produced peptides (NRPs) form a rich source of antibiotics, including more than 20 of these antibiotics that are used in the clinic, such as penicillin G, colistin, vancomycin, and chloramphenicol. Here we report the identification, purification, and characterization of a novel NRP, i.e., brevibacillin 2V (lipo-tridecapeptide), from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.